Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa

Two companies, GtreeBNT and YuYang DNU, will collaborate in a joint venture to develop the investigational drug RGN-137 for the treatment of epidermolysis bullosa. For more details, you can read the source article here, at RegeneRx Biopharmaceuticals’ website.

About Epidermolysis Bullosa

Epidermolysis bullosa (EB) refers to a group of rare and inherited skin disorders that are caused by genetic alterations. According to the NHS website, people with this condition typically have very fragile skin that can develop painful blisters from damage or friction. These blisters are one of the main symptoms of EB, and they can occur on many areas of the skin, including inside the mouth, and on the hands and feet. People with EB may also develop scarred skin, and thickened skin and nails.

About RGN-137

RGN-137 is an investigational drug that is being explored as a potential treatment for EB. It is a topical gel that was originally developed by the company RegeneRx Biopharmaceuticals. According to the company’s website, RGN-137 is a formulation of the peptide Tβ4, and it is thought to speed up dermal (a layer of the skin) wound healing.

Research into RGN-137 for EB

Evidence from pre-clinical studies suggests that RGN-137 can affect several healing pathways, and, furthermore, the gene for Tβ4 was found to be up-regulated following injury. This indicates that Tβ4 is involved in healing.

A Phase 1 clinical trial carried out in 2004 found no serious adverse events and no drug-related adverse events in healthy participants given RGN-137. A subsequent Phase 2 blinded and placebo-controlled study was carried out to investigate the effects of RGN-137 on the treatment of EB.

Gtree and YuYang are now entering into a joint venture called Lenus Therapeutics LLC to develop RGN-137 for the treatment of EB. According to a press release from GtreeBNT, Lenus intends to carry out an open study. Following this, there are plans for a Phase 3 clinical trial that is expected to involve around 200 participants.


Anna Hewitt

Anna Hewitt

Anna is from England and recently finished her undergraduate degree. She has an interest in medicine and enjoys writing. In her spare time she likes to cook, hike, and hang out with cats.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email